Zura Bio Limited (NASDAQ:ZURA) Director Purchases $499,998.72 in Stock

Zura Bio Limited (NASDAQ:ZURA) Director Amit Munshi purchased 159,744 shares of the company’s stock in a transaction on Monday, April 22nd. The shares were bought at an average cost of $3.13 per share, with a total value of $499,998.72. Following the transaction, the director now directly owns 777,384 shares of the company’s stock, valued at approximately $2,433,211.92. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

Zura Bio Stock Performance

ZURA stock opened at $4.41 on Friday. Zura Bio Limited has a 52-week low of $2.00 and a 52-week high of $14.00. The stock’s fifty day simple moving average is $3.19 and its 200-day simple moving average is $4.01.

Analysts Set New Price Targets

Separately, Oppenheimer reissued an “outperform” rating and set a $16.00 price target (down previously from $17.00) on shares of Zura Bio in a research report on Monday, April 1st. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $16.40.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ZURA. Lynx1 Capital Management LP acquired a new position in Zura Bio in the third quarter valued at $65,000. Forefront Analytics LLC acquired a new position in shares of Zura Bio during the third quarter worth about $95,000. Bank of New York Mellon Corp acquired a new position in shares of Zura Bio during the third quarter worth about $224,000. Raymond James & Associates increased its position in shares of Zura Bio by 14.0% during the third quarter. Raymond James & Associates now owns 77,356 shares of the company’s stock worth $511,000 after acquiring an additional 9,481 shares during the last quarter. Finally, Eisler Capital US LLC purchased a new stake in shares of Zura Bio during the third quarter worth about $660,000. Institutional investors and hedge funds own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.